Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S6 kinase beta-1 (RPS6KB1), commonly known as p70S6K, is a serine/threonine protein kinase belonging to the AGC kinase family. It acts as a key downstream effector of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway, specifically activated by mTOR complex 1 (mTORC1) and PDK1. Upon activation, p70S6K phosphorylates the 40S ribosomal protein S6, thereby promoting translation of mRNAs with 5'-terminal oligopyrimidine tracts (5'TOP) and driving protein synthesis, cell growth, cell cycle progression, and cell survival.
Dysregulation and hyperactivation of the PI3K/Akt/mTOR/p70S6K axis are frequently observed in various human pathologies, most notably in cancers such as breast, prostate, and non-small cell lung cancer, where RPS6KB1 gene amplification or overexpression correlates with poor prognosis and therapeutic resistance. Additionally, p70S6K plays a critical role in metabolic disorders like obesity and type 2 diabetes through negative feedback loops that impair insulin receptor substrate-1 (IRS-1) signaling, as well as in neurodegenerative diseases. Consequently, p70S6K has emerged as an attractive therapeutic target. Pharmacological strategies include direct ATP-competitive small-molecule inhibitors (such as LY2584702 and the dual Akt/p70S6K inhibitor M2698) and indirect inhibition via upstream mTORC1 inhibitors like rapamycin. However, clinical development of direct inhibitors has faced challenges, including narrow therapeutic windows, dose-limiting toxicities (such as gastrointestinal distress and pancreatitis), and the potential for compensatory AKT activation resulting from the disruption of negative feedback loops.
ATP-competitive kinase inhibition of p70S6K, blocking downstream phosphorylation of ribosomal protein S6 and inhibiting protein translation; or indirect inhibition via upstream mTORC1 pathway blockade.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S6 kinase beta-1 (p70S6K) (p70S6K).